文献速递心力衰竭与心肌病心律失常

静脉羧基麦芽糖铁对心脏再同步化治疗后心脏逆重构的影响:IRON-CRT试验

The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial.
PubMed 文献 · Eur Heart J · 2021-01-01

IRON-CRT试验将75例CRT植入至少6个月后LVEF仍<45%且缺铁的症状性HFrEF患者随机分配至静脉羧基麦芽糖铁(FCM)或标准治疗。3个月时FCM组LVEF改善显著高于标准治疗组,LVESV降低更明显,且力-频率关系由负转正,功能状态与运动能力亦改善。

要点

  • CRT后LVEF持续<45%且缺铁的HFrEF患者,静脉FCM可改善LVEF和LVESV。
  • FCM使心脏收缩力-频率关系由负斜率转为正斜率。
  • FCM改善堪萨斯城心肌病问卷评分和峰值耗氧量。

核心结论

  • 在CRT后LVEF持续降低且缺铁的HFrEF患者中,静脉FCM治疗可改善LVEF、LVESV及心脏力-频率关系。

研究设计与样本

  • 前瞻性、双盲、随机对照试验,纳入75例CRT植入至少6个月后LVEF<45%且缺铁的症状性HFrEF患者,随机分为FCM组(n=37)和标准治疗组(n=38)。

主要发现

  • 3个月时LVEF变化FCM组为+4.22%(95%CI +3.05%; +5.38%),标准治疗组为-0.23%(95%CI -1.44%; +0.97%),P<0.001。
  • LVESV变化FCM组为-9.72 mL(95%CI -13.5 mL; -5.93 mL),标准治疗组为-1.83 mL(95%CI -5.7 mL; 2.1 mL),P=0.001。
  • LVEDV变化两组差异无统计学意义(P=0.748)。
  • 基线时两组力-频率关系均为负斜率,FCM组3个月时在递增双心室起搏下CCI斜率改善,力-频率关系转为正。
  • FCM组堪萨斯城心肌病问卷评分和峰值耗氧量改善。

临床怎么用

  • 对CRT后LVEF持续降低且缺铁的HFrEF患者,可考虑静脉FCM以改善心脏功能和运动能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Iron deficiency is common in heart failure with reduced ejection fraction (HFrEF) and negatively affects cardiac function and structure. The study the effect of ferric carboxymaltose (FCM) on cardiac reverse remodelling and contractile status in HFrEF. METHODS AND RESULTS: Symptomatic HFrEF patients with iron deficiency and a persistently reduced left ventricular ejection fraction (LVEF <45%) at least 6 months after cardiac resynchronization therapy (CRT) implant were prospectively randomized to FCM or standard of care (SOC) in a double-blind manner. The primary endpoint was the change in LVEF from baseline to 3-month follow-up assessed by three-dimensional echocardiography. Secondary endpoints included the change in left ventricular end-systolic (LVESV) and end-diastolic volume (LVEDV) from baseline to 3-month follow-up. Cardiac performance was evaluated by the force-frequency relationship as assessed by the slope change of the cardiac contractility index (CCI = systolic blood pressure/LVESV index) at 70, 90, and 110 beats of biventricular pacing. A total of 75 patients were randomized to FCM (n = 37) or SOC (n = 38). At baseline, both treatment groups were well matched including baseline LVEF (34 ± 7 vs. 33 ± 8, P = 0.411). After 3 months, the change in LVEF was significantly higher in the FMC group [+4.22%, 95% confidence interval (CI) +3.05%; +5.38%] than in the SOC group (-0.23%, 95% CI -1.44%; +0.97%; P < 0.001). Similarly, LVESV (-9.72 mL, 95% CI -13.5 mL; -5.93 mL vs. -1.83 mL, 95% CI -5.7 mL; 2.1 mL; P = 0.001), but not LVEDV (P = 0.748), improved in the FCM vs. the SOC group. At baseline, both treatment groups demonstrated a negative force-frequency relationship, as defined by a decrease in CCI at higher heart rates (negative slope). FCM resulted in an improvement in the CCI slope during incremental biventricular pacing, with a positive force-frequency relationship at 3 months. Functional status and exercise capacity, as measured by the Kansas City Cardiomyopathy Questionnaire and peak oxygen consumption, were improved by FCM. CONCLUSIONS: Treatment with FCM in HFrEF patients with iron deficiency and persistently reduced LVEF after CRT results in an improvement of cardiac function measured by LVEF, LVESV, and cardiac force-frequency relationship.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Martens P, Dupont M, Dauw J, et al. The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial. Eur Heart J. 2021. PMID: 34185066. doi:10.1093/eurheartj/ehab411

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。